conundrum, yet due to human fascination with goals and targets, they provide cutpoints. On occasions when they have not, there has been intense debate.
In this issue of the Journal, Fernández-Friera et al. (3) report that approximately one-half of the 1,779 subjects with no conventional risk factors and on no medications enrolled in the PESA (Progression of Early Subclinical Atherosclerosis) study had subclinical atherosclerosis as detected by ultrasonography or coronary calcium imaging. In this cohort, w50% were women, and the mean age was w45 years. This analysis of PESA, by including a middle-aged population with no traditional risk factors and not on medications, allowed the investigators to get an unadulterated evaluation of the natural history of atherosclerosis.
The authors found that the prevalence of subclinical atherosclerosis increased as low-density lipoprotein cholesterol (LDL-C) increased, but notably, even at an LDL-C concentration between 60 and 70 mg/dl, 11% of the subjects had subclinical atherosclerosis! Interestingly, the iliofemoral arteries had the highest prevalence of plaque, whereas the coronary calcium score identified the least plaque. The investigators also studied a subgroup (n ¼ 740) with optimal risk factors by current standards (blood pressure: <120/80 mm Hg; fasting glucose: <100 mg/dl; hemoglobin A 1c : <5.7%; total cholesterol: <200 mg/dl). Plaque was detected in Merck, PLx Pharma, and Takeda. Furthermore, cholesterol is not the only conventional risk factor for which the optimal level is not clear. For example, the targets and goals for management of both blood pressure and blood glucose concentration have been the subject of much discussion. Identification of higher risk subgroups in whom the benefit-to-risk ratio may be favorable could be a strategy to consider. Hence, the incremental value of biomarkers such as troponin in gauging risk has been evaluated and demonstrated in primary and secondary prevention populations (11) (12) (13) (14) . Very recently, the 
